ClinicalTrials.gg
CompletedNCT03304821GPAD-3Updated Aug 12, 2026

Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease

A Phase 2 interventional study of GM-CSF and Placebo in Peripheral Artery Disease (PAD), sponsored by Emory University. Completed at 1 site in United States. Open to participants aged 21 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Emory University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 4 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jul 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
21 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 479 studies in Peripheral Arterial Disease with a site in United States — 82 open to participants now, 101 under way, 10 of them phase 3. Peripheral Arterial Disease · United States.

Enrollment
133rd of 373
114 · median 64
Started
2017
with 37 others
Phase 2
48 of 479
4 open now
Registered
262nd of 479
by date

Among the 479 studies in Peripheral Arterial Disease with a site in United States, this one is the 133rd largest by enrollment of the 373 interventional ones that give a count, is one of 38 that started in 2017, is one of 48 in phase 2, and was the 262nd registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

82 of the 479 studies in Peripheral Arterial Disease with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 21 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 479 studies in Peripheral Arterial Disease with a site in United States, or all of them as a file.
02

Study summary

Peripheral artery disease (PAD) is a disease in which plaque builds up in the arteries that carry blood to the head, organs, and limbs. PAD usually occurs in the arteries in the legs, but can affect any arteries. Over time, plaque can harden and narrow the arteries which limits the flow of oxygen-rich blood to organs and other parts of the body. Blocked blood flow to the arteries can cause pain and numbness. The pain is usually worse with exercise and gets better with rest. PAD can raise the risk of getting an infection which could lead to tissue death and amputation. This study is investigating whether granulocyte-macrophage colony stimulating factor (GM-CSF) improves symptoms and blood flow in people with PAD. GM-CSF is a drug that is used to stimulate the bone marrow to release stem cells. Participants in the study will be randomly selected to receive GM-CSF or a placebo. After a four-week screening phase, participants will receive injections of GM-CSF or a placebo three times a week for three-weeks. Three months later, participants will again receive injections of GM-CSF or placebo three times a week for three-weeks. At six months, the study team will follow up to see if the group that received GM-CSF had more improvement than the group that received placebo.

Read the detailed description

Atherosclerotic peripheral artery disease (PAD) of the lower extremities afflicts up to 8% of the U.S. population and lack of adequate sustainable therapies necessarily results in severe morbidity and increased mortality. Both experimental and current clinical data indicate that GM-CSF has the capacity to mobilize a variety of progenitor cells (PCs), including endothelial PCs that appear to improve ischemia.

This study builds on the findings of prior research which showed improvements in claudication symptoms after treatment with GM-CSF. This study aims to answer whether repeat administration of GM-CSF at 3 months will further improve symptoms. The researchers will investigate in a double-blind placebo-controlled randomized study whether 3 weeks of three-times-a-week injection of GM-CSF will improve measures of ischemia in patients with intermittent claudication.

This study will recruit 176 participants with atherosclerotic PAD and claudication. After screening for inclusion and exclusion criteria, eligible subjects will be trained to perform subcutaneous injections and instructed to walk until they develop claudication or symptomatic limitation at least three times a day for 4 weeks. At the end of the 4-week period, subjects will undergo baseline testing and will be randomized to receive 500 μg/day of GM-CSF thrice weekly for 3 weeks (group A) or a placebo (group B). After 3 months, follow-up endpoint testing will be performed. Subjects in group A will then receive the second administration of 500 μg/day of subcutaneous GM-CSF thrice weekly for another 3 weeks and be followed for another 3 months for endpoint measurements, while Group B subjects will receive a matching placebo. The primary outcome is change in walking performance in the active treatment group after 6 months compared to the placebo group. The secondary outcome includes change in peak walking time at 6 months, changes in circulating progenitor cell levels, ankle brachial index (ABI), walking impairment questionnaire (WIQ) scores, and 36-item Short-Form Health Survey (SF-36) scores. Long-term follow up, by way of a telephone call, will occur with each participant one, two and three years after they enrolled in the study to administer questionnaires and collect adverse event data.

In response to the Coronavirus Disease 2019 (COVID-19) crisis on April 3, 2020 the Institutional Review Board (IRB) approved temporary modifications to this study to postpone study visits that do not involve active drug/placebo use.

03

Conditions studied

  • Peripheral Artery Disease (PAD)

Keywords

  • Atherosclerotic peripheral artery disease
  • Granulocyte-macrophage colony stimulating factor (GM-CSF)
  • Atherosclerosis
  • Cardiology
  • Vascular disease
04

Who can participate

Ages eligible
21 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female subjects must be (a) , (b) surgically sterile or (c) use adequate and have a negative pregnancy test within 3 days prior to administration of study drug and should not be breastfeeding.
  • Documented symptomatic PAD
  • Clinically stable (at least 2 months prior to enrollment) history of intermittent claudication or walking impairment (Rutherford Class II) with no change in symptom severity in the 2 months prior to screening.
  • On statin therapy for previous 3 months prior to enrollment, unless statin intolerant.
  • Peak Walking Time (PWT) between 1 and 12 minutes on a standardized Gardner treadmill protocol or modified Gardner protocol or less than 12 minutes on a modified Bruce protocol in case PWT on Gardner protocol is more than 12 minutes.
  • A Doppler-derived ankle-brachial index (ABI) of \< 0.90 in the symptomatic limb after 10 minutes of rest at screening. For subjects with an ABI of >1.3 (non-compressible arteries) a Toe-Brachial Index (TBI) of \< 0.70 must be obtained for subject qualification, or if ABI is > 0.9 to 1.0 , and a reduction of 20% in ABI measured within 1 minute of treadmill testing.
  • On appropriate and stable medical therapy for atherosclerosis for at least 2 months prior to enrollment.
  • Able to give .
  • Diabetics with a dilated eye exam excluding proliferative retinopathy in the previous 12 months prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  • Recent or current active infections (treated with antibiotics)
  • Recent (6 months prior to randomization) or current active cancer undergoing treatment
  • Recent (3 months prior to randomization) change in statin or cilostazol therapy
  • Critical limb ischemia either chronic (Rutherford Class >II) or acute ischemia manifested by rest pain, ulceration, or gangrene
  • Recent (3 months prior to randomization) lower extremity vascular surgery, angioplasty or lumbar sympathectomy
  • Planned participation in a structured exercise treatment protocol in the future or within period of study
  • Prior myeloid
  • Recent (3 months prior to randomization) Unstable angina, myocardial infarction, (TIA), stroke or revascularization
  • Severe heart failure (Class III or IV) or heart muscle disease
  • Limitation on exercise for symptoms other than intermittent claudication such as arthritis or dyspnea
  • Below- or above-knee amputation
  • Wheelchair confinement
  • Use of a walking aid other than a cane
  • Walking impairment for reasons other than PAD e.g. Parkinson's disease
  • Uncontrolled diabetes mellitus (defined as > 10.0)
  • Chronic renal disease (creatinine of >2.5 mg/dl) or hepatic disease (> 3 X elevations in (AST) and alanine aminotransferase (ALT))
  • White blood cell count \< 3k/cmm
  • (HGB) \< 10g/dL
  • Blood Pressure Systolic >180 and/or Diastolic >100
  • Taking drugs
  • Ophthalmologic conditions associated with a neo-vascular response
  • Alcohol or drug abuse, or any other disease process that, in the opinion of the PI, will interfere with the ability of the patient to participate in the study
  • Inability to attend study visits
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    Granulocyte-macrophage Colony Stimulating Factor (GM-CSF)

    Participants receiving 500µg of granulocyte-macrophage colony stimulating factor (GM-CSF), administered subcutaneously. Prior to randomization to a study arm, eligible participants are trained to perform subcutaneous injections and instructed to walk at least three times a day until they develop claudication or symptomatic limitation for 4 weeks.

    Drug: GM-CSF

  • Placebo comparator
    Placebo

    Participants receiving 500µg of a placebo, administered subcutaneously. Prior to randomization to a study arm, eligible participants are trained to perform subcutaneous injections and instructed to walk at least three times a day until they develop claudication or symptomatic limitation for 4 weeks.

    Drug: Placebo

Interventions

  • DrugGranulocyte-Macrophage Colony-Stimulating FactorStudies of Granulocyte-Macrophage Colony-Stimulating FactorGranulocyte-Macrophage Colony-Stimulating Factor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will self-administer 500 μg/day of GM-CSF, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of subcutaneous GM-CSF, three times per week for another 3 weeks and then will be followed for another 3 months.

    Also known as: Sargramostim, Leukine

  • DrugPlacebo

    Participants will self-administer 500 μg/day of a placebo, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of a placebo administered subcutaneously, three times per week for another 3 weeks and then will be followed for another 3 months.

06

What researchers measure

Primary outcomes

  1. Change in 6-minute walk distance

    Participants walk up and down a 100-foot hallway for 6 minutes to cover the maximum distance possible. The distance, measured in meters, completed after 6 minutes will be recorded. The primary outcome examines walking distance following two consecutive 3-monthly administrations of the study treatments.

    Time frame: Baseline, Month 6

Secondary outcomes

  1. Change in Peak Walking Time (PWT)

    Graded treadmill exercise testing is performed using the Gardner protocol where the treadmill speed is kept at 2 mph and the grade starts at 0 and inclines by 2% every two minutes. The peak walking time (PWT) is the time (measured in seconds) until exercise is terminated because of severe claudication (pain in legs). Exercise testing is performed twice and longest time is used as the PWT for that study visit.

    Time frame: Baseline, Month 6

  2. Change in Peak Walking Time (PWT) From First Through Second Treatment

    To investigate whether there is further improvement with GM-CSF administered twice compared to a single administration, PWT at Month 6 compared to Month 3 is examined. Graded treadmill exercise testing is performed using the Gardner protocol where the treadmill speed is kept at 2 mph and the grade starts at 0 and inclines by 2% every two minutes. The peak walking time (PWT) is the time (in seconds) until exercise is terminated because of severe claudication (pain in legs). Exercise testing is performed twice and longest time is used as the PWT for that study visit.

    Time frame: Month 3, Month 6

  3. Change in Peak Walking Time (PWT) After Single Treatment

    To investigate whether there is improvement following a single treatment of GM-CSF, PWT at Month 3 compared to Baseline is examined. Graded treadmill exercise testing is performed using the Gardner protocol where the treadmill speed is kept at 2 mph and the grade starts at 0 and inclines by 2% every two minutes. The peak walking time (PWT) is the time (in seconds) until exercise is terminated because of severe claudication (pain in legs). Exercise testing is performed twice and longest time is used as the PWT for that study visit.

    Time frame: Baseline, Month 3

  4. Change in 6-minute Walk Distance From First Through Second Treatment

    To investigate whether there is further improvement with GM-CSF administered twice compared to a single administration, the examine walking distance at Month 6 compared to Month 3 is examined. Participants walk up and down a 100-foot hallway for 6 minutes to cover the maximum distance possible. The distance, measured in meters, completed after 6 minutes is recorded.

    Time frame: Month 3, Month 6

  5. Change in 6-minute Walk Distance After Single Treatment

    To investigate whether there is improvement following a single treatment of GM-CSF, the walking distance at Month 3 compared to Baseline is examined. Participants walk up and down a 100-foot hallway for 6 minutes to cover the maximum distance possible. The distance, measured in meters, completed after 6 minutes is recorded.

    Time frame: Baseline, Month 3

  6. Change in Walking Impairment Questionnaire (WIQ): Walking Distance Score

    The Walking Impairment Questionnaire (WIQ) domain of walking distance asks respondents to rate how difficult it is to walk around home, as well as distances of 50, 150, 300, 600, 900 and 1500 feet. Possible responses are: not hard (4), slightly difficult (3), somewhat difficult (2), very difficult (1), and unable to do (0). Total raw scores range from 0 to 28 with higher scores indicating increased ability to walk further distances.

    Time frame: Baseline, Month 3, Month 6, Month 9, Year 1

  7. Change in Walking Impairment Questionnaire (WIQ): Walking Speed Score

    The Walking Impairment Questionnaire (WIQ) domain of walking speed asks respondents to rate how difficult it is to walk the distance of one block slowly, at an average speed, quickly, and running/jogging. Possible responses are: not hard (4), slightly difficult (3), somewhat difficult (2), very difficult (1), and unable to do (0). Total raw scores range from 0 to 16 with higher scores indicating increased ability to walk fast.

    Time frame: Baseline, Month 3, Month 6, Month 9, Year 1

  8. Change in Walking Impairment Questionnaire (WIQ): Stair Climbing Score

    The Walking Impairment Questionnaire (WIQ) domain of stair climbing asks respondents to rate how difficult it is to climb 1, 2, and 3 flights of stairs. Possible responses are: not hard (4), slightly difficult (3), somewhat difficult (2), very difficult (1), and unable to do (0). Total raw scores range from 0 to 12 with higher scores indicating better ability to climb stairs.

    Time frame: Baseline, Month 3, Month 6, Month 9, Year 1

  9. Change in 36-item Short-Form Health Survey (SF-36) Score

    36-item Short-Form Health Survey (SF-36) consists of eight scaled scores for the domains of: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. The domains can be summarized to represent two distinct concepts for a Physical Component Summary (PCS) and a Mental Component Summary (MCS). Study participants respond to questions relating to their health and activity level by selecting from a variety of Likert scale and yes/no response options. Each scale is directly transformed into a 0-100 scale and lower scores indicate more disability (a score of 0 equates to maximum disability while a score of 100 indicates no disability). This study examines the Physical Component Summary (PCS) score as well as all domains.

    Time frame: Baseline, Month 3, Month 6, Month 9, Year 1

  10. Change in Claudication Onset Time (COT)

    Claudication onset time (COT) during the treadmill exercise will be recorded along with the peak walking time (PWT). The claudication onset time (COT) is the duration of exercise until onset of the participant's typical claudication. This is differentiated from the peak walking time (PWT) which is the time until exercise is terminated because of severe claudication. Graded treadmill exercise testing will be performed using the Gardner protocol where the treadmill speed is kept at 2 mph and the grade starts at 0 and inclines by 2% every two minutes.

    Time frame: Baseline, Month 3, Month 6, Month 9

  11. Change in Ankle-Brachial Index (ABI)

    To obtain the ankle-brachial index (ABI), bilateral upper and lower extremity blood pressure cuffs are inflated about 30 millimeters of mercury (mmHg) above the systolic pressure. Doppler flow signals are used to detect the reappearing perfusion while reducing the cuff pressure. The results is expressed as a segmental/arm pressure ratio (ABI index). The highest pressure of the two arms will be used for calculating the ABI. The average ratio is about 1.0+/-0.10; an index of 0.90 or lower is considered abnormal. In patients with calcific, non-compressible arteries (certain diabetics) where ABI measurements are unreliable, a toe/ arm pressure index ratio will be performed, with a 2.5 cm cuff used on the great or second toes. A toe/arm index less than 0.65 is considered abnormal.

    Time frame: Baseline, Month 3, Month 6, Month 9

  12. Change in Foot Transcutaneous Oxygen Tension (TcPO2)

    Foot transcutaneous oxygen tension (TcPO2) is a noninvasive way to measure peripheral arterial disease. TcPO2 is obtained with a monitor before exercise after the patients have been standing for three minutes and is monitored throughout exercise. Values are recorded at initial claudication distance, absolute claudication distance, and after recovery from exercise. A commonly used cut point is 60 millimeters of mercury (mmHg), with values below this indicating the presence of peripheral arterial disease.

    Time frame: Baseline, Month 3, Month 6, Month 9

  13. Number of Circulating Mononuclear Cells Expressing CD34

    The number of circulating mononuclear cells expressing the PC specific epitopes CD34 is counted using fluorescent activated sorting (FACS).

    Time frame: Baseline, Week 3, Month 3, Week 15, Month 6, Month 9

  14. Number of Circulating Mononuclear Cells Expressing CD133

    The number of circulating mononuclear cells expressing the PC specific epitopes CD133 is counted using fluorescent activated sorting (FACS).

    Time frame: Baseline, Week 3, Month 3, Week 15, Month 6, Month 9

  15. Number of Circulating Mononuclear Cells Expressing VEGF2R (KDR)

    The number of circulating mononuclear cells expressing the PC specific epitopes VEGF2R (KDR) is counted using fluorescent activated sorting (FACS).

    Time frame: Baseline, Week 3, Month 3, Week 15, Month 6, Month 9

  16. Number of Circulating Mononuclear Cells Expressing CXCR4

    The number of circulating mononuclear cells expressing the PC specific epitopes CXCR4 is counted using fluorescent activated sorting (FACS).

    Time frame: Baseline, Week 3, Month 3, Week 15, Month 6, Month 9

07

Study locations

1 site
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
08

References and documents

Publications

  • Mehta A, Mavromatis K, Ko YA, Rogers SC, Dhindsa DS, Goodwin C, Patel R, Martini MA, Prasad M, Mokhtari A, Hesaroieh IG, Frohwein SC, Kutner MH, Harzand A, Wells BJ, Duwayri Y, Alabi O, Rajani RR, Brewster LP, Waller EK, Quyyumi AA. Rationale and design of the granulocyte-macrophage colony stimulating factor in peripheral arterial disease (GPAD-3) study. Contemp Clin Trials. 2020 Apr;91:105975. doi: 10.1016/j.cct.2020.105975. Epub 2020 Mar 4. PubMed 32145440 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Jul 2025, 90 months.

Of 27 phase 2 interventional studies under Peripheral Arterial Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 90 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2017
First posted
Oct 9, 2017
StartActual
Dec 19, 2017
Primary completionActual
Jul 5, 2025
CompletionActual
Jul 5, 2025
Results delay requested
Jul 3, 2026
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03304821
Lead sponsor
Emory University
Responsible party
Arshed A. Quyyumi (Professor, Emory University) — Principal investigator
First posted
Oct 9, 2017
Start date
Dec 19, 2017
Primary completion
Jul 5, 2025
Completion
Jul 5, 2025
Last update
Aug 12, 2026

Study contacts

Arshed Quyyumi, MD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Granulocyte-Macrophage Colony-Stimulating Factor

Start the discussion